DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Wei L, Zhang M, Xu M. , et al.
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
J Gastroenterol Hepatol 2016;
31 (11) 1860-1867
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.